Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer (ICEBERG-PC)
ICEBERG-PC: Integrated Clinical Evaluation of Biomarkers, Radiogenomics, and Genomics in Prostate Cancer: A Single-Site AmbidirectionalObservational Outcomes Cohort
Management of prostate cancer increasingly integrates conventional clinicopathologic risk factors with multiparametric magnetic resonance imaging (mpMRI), targeted and systematic biopsy, molecular imaging, and selected tissue-based genomic biomarkers. Contemporary guidelines emphasize risk-adapted shared decision-making and allow selective use of tissue-based genomic biomarkers when additional risk stratification may alter management discussions.
研究概览
地位
条件
详细说明
The central rationale is to create a source-controlled, longitudinal prostate cancer outcomes cohort in which routine-care genomics, PSMA PET, mpMRI, MRI/ultrasound fusion biopsy, pathology, treatment, and functional outcomes can be analyzed together. The historical component will provide a background population for understanding treatment patterns and outcomes when Decipher® and/or PSMA PET were not obtained. It will not be treated as a formal randomized or concurrent comparator arm. This study is designed to observe that real-world clinical process without assigning testing, imaging, or treatment.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Sachin Vyas, MS,PhD
- 电话号码:336-713-4098
- 邮箱:Sachin.vyas@advocatehealth.org
学习地点
-
-
North Carolina
-
Winston-Salem、North Carolina、美国、27157
- Wake Forest University Health Sciences
-
首席研究员:
- Thomas Polascik, MD
-
接触:
- Sachin Vyas, MS, PhD
- 电话号码:336-713-4098
- 邮箱:Sachin.Vyas@Advocatehealth.org
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Diagnosis of prostate cancer
描述
Inclusion Criteria:
- Age ≥18 years.
- Diagnosis of prostate cancer documented in the institutional medical record. Prostate adenocarcinoma will constitute the principal analytic population, while other prostate cancer histology's may be retained for descriptive background analyses when clinically relevant.
- Evaluation, diagnosis, treatment, or follow-up within or beyond Advocate Health Wake Forest Baptist / Wake Forest University School of Medicine and availability of sufficient clinical information for at least one study objective.
- For the prospective component, first ascertainment after protocol activation will be conducted through routine clinical records or institutional clinical data systems.
- For the historical background component, available institutional records predating protocol activation will be used to characterize prostate cancer presentation, management, and outcomes
Exclusion Criteria:
- Insufficient clinical information to establish the relevant diagnosis, treatment, or outcome for a proposed analysis.
- Records that cannot be used under applicable institutional privacy, data-governance, or IRB requirements.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:RETROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Patients been diagnosed with the prostate cancer
To determine how clinically obtained tumor genomic and transcriptomic features, phenotype, real-world treatment selection, and longitudinal oncologic outcomes |
This study involves no study specific intervention |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Prostate-Specific Membrane Antigen (PSMA) PET disease extent
大体时间:up to 5 years
|
Prostate-Specific Membrane Antigen (PSMA) PET disease extent among patients with clinically obtained Decipher® and PSMA PET, classified as localized versus nonlocalized disease using available molecular-imaging staging data. |
up to 5 years
|
合作者和调查者
调查人员
- 首席研究员:Thomas Polascik, MD、Wake Forest University Health Sciences
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.